P185
Engineered T cells for cancer therapy.Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection.Chimeric Antigen Receptor T Cells against CD19 for Multiple MyelomaIbrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemiaCAR-T Cell Therapies From the Transfusion Medicine PerspectiveCapsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors.Adoptive immunotherapy for cancer or viruses.Chimeric antigen receptor T cell therapy: 25years in the making.Chimeric Antigen Receptor T-Cells: New Approaches to Improve Their Efficacy and Reduce ToxicityCD19-Targeted CAR T Cells: A New Tool in the Fight against B Cell Malignancies.A cell-based artificial antigen-presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion and long-term growth of CD4 T lymphocytes.Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB.Designing CAR T cells for glioblastomaCD8(+) T-cell responses to adeno-associated virus capsid in humans.A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug deliveryAnti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomasHLA tetramer-based artificial antigen-presenting cells for stimulation of CD4+ T cellsAbstracts of the 29th Annual Scientific Meeting of the Society for Immunotherapy of Cancer (SITC)Biomanufacturing for clinically advanced cell therapiesToxicities associated with immunotherapies for hematologic malignanciesAdoptive T-Cell Transfer: Harnessing Immune Cells to Combat DiseaseEx vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig–coated artificial antigen-presenting cellsProlactin as a Chemoattractant for Human Breast CarcinomaEngineered CRISPR-Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editingSynthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor responseGene editing for immune cell therapiesImmunotherapy for Glioblastoma: Adoptive T-cell StrategiesASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsWishing on a CAR: Understanding the Scope of Intrinsic T-cell Deficits in Patients with CancerEquity and diversity in academic medicine: a perspective from the JCI editorsCRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastomaTisagenlecleucel CAR T-cell therapy in secondary CNS lymphomaCAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicityPublisher Correction: Engineered CRISPR-Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing
P50
Q34080368-275F90A9-BC79-49AE-B2A2-91C7D8347B81Q34517676-834E3C7B-364B-4D0B-98E7-4129CDE7A3BAQ36284584-79CB3AF9-68B2-4659-8FBD-B3C057D6DF92Q36651344-8AA0A6EB-7689-4B69-ACDC-F580413A39C3Q37022738-572A8A4D-C654-4F69-AC6B-E0F4B86E9C64Q37209197-A9C4E029-4B1F-4773-A9E9-45D0EA2A1B59Q38178359-011AAFF1-CFA1-476D-BB62-96DEE4917D96Q38634950-5462705C-A35F-4227-BC95-D521675E4DAEQ38640367-F26787AB-5A42-4107-BB73-7D5B5E11E46BQ38658226-32619B88-1484-4790-AF2C-6CAE5FDEA19FQ40681451-80202889-2389-4E66-ACAC-5548FBEDD7DCQ40753339-8702842F-BE80-428F-AD7F-545FC44E7F00Q41964506-362E0E5B-4917-41DE-BF95-3A1C364A562DQ45406111-3D3D8059-ABF1-49EC-A8EA-892E43739802Q45946525-249C56D6-6FDE-43DF-B9B3-8C97D3C94A68Q56797729-A5AAA7C1-B191-41CE-945C-2D72480CAAE3Q57024658-28133DF9-9C8D-491E-9E3E-A5FAC35F9DCBQ57158932-B7B1C601-00C3-4CB1-8B7B-9D9D359DF486Q59400460-37F332BC-F3D7-49CB-899D-D6980BE28EDDQ61954919-B11E8002-2DF1-4A52-94EA-3D6D0D720F7EQ61954924-35EAAA4F-E0BD-4DAD-966C-45D77BD1903CQ61954932-0F1C07DF-7011-41F8-BA50-1AE39B0E3609Q61954967-663BE20B-F92A-4B25-A590-119205F1B74FQ61954978-F59633CB-792A-46CB-8F0D-962043D69920Q62490800-902B7E5D-6DF9-4236-A8CC-DB71B3FD790BQ64064162-A4E551A9-BFA2-45CF-BDE5-678FEF4DFDEFQ67201058-E09ED60E-5748-4AA8-A557-AF25571499A1Q67201060-D0EE5741-6077-42D3-9772-92AA5522EF0BQ67201061-4A9351BA-82D7-4FF4-BD54-CE99ADDED700Q67201062-4440357D-28C4-4E21-9927-D792BD94828BQ90121123-CF5FB737-4F07-4CFD-950C-295E858120B0Q91284190-7B786A13-4CA6-4C5C-8724-88B07A1A8CCDQ92000371-3E1BC78C-7DC8-486B-8692-99F5390078ECQ92093435-58016596-E688-45DA-BAEF-263F59B61110Q96431877-2904B7C9-D1A2-4AAB-ABE3-F38927BB9D9A
P50
description
American immunologist
@en
wetenschapper
@nl
հետազոտող
@hy
name
Marcela V Maus
@ast
Marcela V Maus
@en
Marcela V Maus
@es
Marcela V Maus
@nl
Marcela V Maus
@sl
type
label
Marcela V Maus
@ast
Marcela V Maus
@en
Marcela V Maus
@es
Marcela V Maus
@nl
Marcela V Maus
@sl
altLabel
Marcela Maus
@en
prefLabel
Marcela V Maus
@ast
Marcela V Maus
@en
Marcela V Maus
@es
Marcela V Maus
@nl
Marcela V Maus
@sl
P108
P69
P106
P108
P184
P1960
dpxJXWgAAAAJ
P21
P31
P496
0000-0002-7578-0393